195 related articles for article (PubMed ID: 14676117)
1. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
[TBL] [Abstract][Full Text] [Related]
4. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
8. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
10. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
[TBL] [Abstract][Full Text] [Related]
11. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
Blackhall FH; Ranson M; Radford JA; Hancock BW; Soukop M; McGown AT; Robbins A; Halbert G; Jayson GC;
Br J Cancer; 2001 Feb; 84(4):465-9. PubMed ID: 11263437
[TBL] [Abstract][Full Text] [Related]
13. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder JA; Shields AF; Zalupski M; Chaplen R; Heilbrun LK; Arlauskas P; Philip PA
Clin Cancer Res; 2001 Jan; 7(1):38-42. PubMed ID: 11205915
[TBL] [Abstract][Full Text] [Related]
17. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
18. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]